KeyCorp Boosts Livongo Health (NASDAQ:LVGO) Price Target to $105.00

Livongo Health (NASDAQ:LVGO) had its price target increased by equities research analysts at KeyCorp from $85.00 to $105.00 in a research note issued to investors on Tuesday, The Fly reports. KeyCorp’s target price suggests a potential upside of 13.27% from the company’s current price.

A number of other analysts have also weighed in on LVGO. Cowen raised their price objective on shares of Livongo Health from $69.00 to $88.00 and gave the company an “outperform” rating in a research note on Thursday, June 25th. Benchmark started coverage on shares of Livongo Health in a research note on Tuesday, April 21st. They set a “buy” rating and a $55.00 price objective for the company. Royal Bank of Canada raised their price objective on shares of Livongo Health from $45.00 to $53.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Stifel Nicolaus started coverage on shares of Livongo Health in a research note on Thursday, March 19th. They set a “buy” rating and a $30.00 price objective for the company. Finally, Canaccord Genuity raised their price objective on shares of Livongo Health from $65.00 to $69.00 and gave the company a “buy” rating in a research note on Wednesday, June 3rd. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $62.71.

NASDAQ LVGO traded up $15.07 during trading hours on Tuesday, reaching $92.70. 13,911,758 shares of the company’s stock traded hands, compared to its average volume of 3,661,919. Livongo Health has a 52-week low of $15.12 and a 52-week high of $82.50. The firm has a market cap of $7.12 billion and a PE ratio of -80.61. The firm has a 50-day simple moving average of $64.38 and a 200 day simple moving average of $38.90.

Livongo Health (NASDAQ:LVGO) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.07. Livongo Health had a negative net margin of 22.05% and a negative return on equity of 11.81%. The company had revenue of $68.80 million during the quarter, compared to analysts’ expectations of $66.11 million. Livongo Health’s revenue for the quarter was up 114.3% on a year-over-year basis. As a group, research analysts expect that Livongo Health will post -0.37 earnings per share for the current fiscal year.

In other Livongo Health news, Chairman Glen Tullman sold 170,000 shares of Livongo Health stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $57.44, for a total transaction of $9,764,800.00. Following the transaction, the chairman now owns 1,071,932 shares of the company’s stock, valued at $61,571,774.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hemant Taneja sold 300,000 shares of Livongo Health stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $52.88, for a total transaction of $15,864,000.00. The disclosure for this sale can be found here. Insiders have sold 515,009 shares of company stock valued at $28,872,089 over the last 90 days. 13.00% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the business. American International Group Inc. lifted its holdings in Livongo Health by 229.8% during the first quarter. American International Group Inc. now owns 30,466 shares of the company’s stock valued at $869,000 after purchasing an additional 21,227 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Livongo Health by 66.2% in the first quarter. Morgan Stanley now owns 824,854 shares of the company’s stock worth $23,533,000 after buying an additional 328,577 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Livongo Health by 181.1% in the first quarter. BlackRock Inc. now owns 3,598,006 shares of the company’s stock worth $102,652,000 after buying an additional 2,318,002 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Livongo Health by 167.5% in the first quarter. Bank of New York Mellon Corp now owns 177,224 shares of the company’s stock worth $5,056,000 after buying an additional 110,982 shares in the last quarter. Finally, Bank of Montreal Can purchased a new position in shares of Livongo Health in the fourth quarter worth $47,000. 38.70% of the stock is currently owned by institutional investors and hedge funds.

About Livongo Health

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

Featured Article: What are high-yield dividend stocks?

The Fly

Analyst Recommendations for Livongo Health (NASDAQ:LVGO)

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.